Navigation Links
MAP Pharmaceuticals Announces Phase 3 Study of Unit Dose Budesonide in Children With Asthma Did Not Meet Primary Endpoints
Date:2/23/2009

MOUNTAIN VIEW, Calif., Feb. 23 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) announced today results of its initial Phase 3 clinical trial of Unit Dose Budesonide (UDB) for the potential treatment of children with asthma. The Company announced that the clinical trial did not meet its co-primary endpoints, asthma control as assessed by changes from baseline in nighttime and daytime composite symptom scores, in either of the doses evaluated, when compared with placebo. Median nebulization times were less than four minutes for both doses in the study. Initial review of the data has not identified any serious adverse events attributed to study drug. Patients continue to be treated in a 52-week safety study to collect long-term safety data on the two doses under investigation.

"Based on our initial review of these data, both the placebo and study groups experienced improvements in asthma symptoms, but the differences were not statistically significant. We observed a higher than expected response in the placebo group, starting as early as one week after randomization and continuing throughout the 12 week treatment period," said Timothy S. Nelson, Chief Executive Officer of MAP Pharmaceuticals. "We and our partner, AstraZeneca, are conducting further analyses of these data to determine appropriate next steps going forward for the program. The Company remains dedicated to developing therapies for children suffering from asthma."

About the AstraZeneca Collaboration

MAP Pharmaceuticals and AstraZeneca have a collaboration agreement to develop and commercialize UDB in the United States, and AstraZeneca has rights to develop and commercialize UDB outside of the United States.

About the Study

In this randomized, double-blind, placebo-controlled study, 360
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. AstraZenecas Partner, MAP Pharmaceuticals, Announces Phase 3 Study of Unit Dose Budesonide in Children with Asthma Did Not Meet Primary Endpoints
2. Shareholder Class Action Filed Against Rigel Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
3. Access Licenses ProLindac(TM) and MuGard(TM) to JCOM Ltd, an Affiliate of DONG-A Pharmaceuticals in Korea
4. Inspiration Biopharmaceuticals, Inc. Initiates Phase 1 Clinical Trial of IB1001 for the Treatment of Hemophilia B
5. Endo Pharmaceuticals Announces Research Collaborations to Develop Novel Pain Treatments and Discover Potential Cancer Treatments
6. Sequoia Pharmaceuticals Presents Proof of Clinical Concept of SPI-452, a Novel Pharmacokinetic Enhancer
7. Indevus Pharmaceuticals Announces PRO 2000 Found to Show Promise in Large HIV Prevention Study
8. Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV
9. Raptor Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2a Clinical Trial in Non-Alcoholic Steatohepatitis (NASH)
10. Oramed Pharmaceuticals Completes Proof of Concept Study of Insulin Suppository
11. Alseres Pharmaceuticals Completes Enrollment in First Stage of the Altropane(R) POET-2 Phase III Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... -- WuXi PharmaTech (Cayman) Inc. (NYSE:  WX), a leading ... pharmaceutical, biotechnology, and medical device industries with operations in ... United States , congratulates our partner TaiMed Biologics ... for ibalizumab (TMB355). The FDA designates a drug as ... in combination with one or more other drugs, to ...
(Date:2/27/2015)... - La ... monitoraggio dell,infarto congestizio (CHF - Congestive Heart Failure) ...   Vectorious Medical Technologies, società ... il monitoraggio cardiaco destinato a pazienti affetti da ... concluso una raccolta di finanziamenti per 5 milioni ...
(Date:2/27/2015)... Feb. 27, 2015  Boston Scientific Corporation (NYSE: ... Barclays 2015 Annual Healthcare Conference on March 10 in ... Dan Brennan , executive vice president and chief financial ... Relations, will participate in a 25-minute question and answer ... approximately 1:05 p.m. ET. Following a 5-minute break, a ...
Breaking Medicine Technology:WuXi Congratulates TaiMed Biologics on Receiving Breakthrough Therapy Designation from U.S. FDA 2Vectorious Medical Technologies completa una raccolta di 5 milioni di dollari 2Boston Scientific to Participate in the Barclays 2015 Annual Healthcare Conference 2
... joined the ranks of a select group.  The 41-bed provider ... one of only 100 hospitals to do so as of ... Health IT Policy Committee, an industry group that works with ... (ONC-HIT). The Jacksboro, Texas-based hospital is leveraging the ...
... 2011 Elekta announced it has received approval ... system in the European Union. Integrity R1.1 combines ... rate (CVDR) and interdigitation capabilities for Elekta,s MLCi2™ ... of delivery techniques -- such as Intensity Modulated ...
Cached Medicine Technology:Faith Community Hospital Joins Meaningful Use Trailblazers 2Faith Community Hospital Joins Meaningful Use Trailblazers 3New Digital Linear Accelerator Control System Demonstrates Treatment Time Savings of Up to 30 Percent 2New Digital Linear Accelerator Control System Demonstrates Treatment Time Savings of Up to 30 Percent 3
(Date:2/28/2015)... Portland, OR (PRWEB) February 28, 2015 ... Duncan Fletcher of Game Change ... and Shannon Leinert about the benefits of athlete development ... underscores some of the unique challenges that athletes face ... on-field and future success. , Fletcher became involved in ...
(Date:2/28/2015)... March—also known as National Brain ... ourselves and others that suspected head injuries, especially ... (ANS). , Concussions are a form of traumatic ... TBIs. There are 1.6-3.8 million sports-related concussions per ... it is a brain injury. Many athletes suffer ...
(Date:2/28/2015)... For those people who are unable to ... Applied Research Foundation (Meso Foundation) will broadcast its ... at 9:30 AM. , The live broadcast is free ... be accessed through any browser on a computer or ... is a unique event that covers important treatment information ...
(Date:2/28/2015)... India Network Foundation, a ... insurance programs for visitors coming to the United States ... traveling to the United States are suffering from one ... pressure. These diseases are so common among the elderly ... medical conditions. There were 66.8 million cases of diabetes ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 The noted ... announce that they have officially relaunched their website. The ... user-friendly, but it contains a new section about their ... to read the full biographies of each Friedman Dental ... of the website was designed to provide our patients ...
Breaking Medicine News(10 mins):Health News:SCI TV Covers Athlete Development with Duncan Fletcher 2Health News:SCI TV Covers Athlete Development with Duncan Fletcher 3Health News:Atlantic NeuroSurgical Specialists (ANS) Focus on National Brain Injury Awareness Month to Educate the General Public on Head Trauma 2Health News:Atlantic NeuroSurgical Specialists (ANS) Focus on National Brain Injury Awareness Month to Educate the General Public on Head Trauma 3Health News:Mesothelioma Cancer Research Foundation Broadcasting Symposium Live 2Health News:India Network Announces Pre-existing Condition Health Insurance Coverage for Diabetic Visitors of All Ages Traveling to the United States 2Health News:India Network Announces Pre-existing Condition Health Insurance Coverage for Diabetic Visitors of All Ages Traveling to the United States 3Health News:Friedman Dental Group Announces Their Updated Website 2
... The Crossings, the Texas Hill Country spa retreat, just ... Day for each day booked. From March 8 ... three healthy gourmet meals, gracious and comfortable accommodations with beautiful ... day. In addition, The Crossings offers a heated infinity ...
... Versus Technology,Inc. ("Versus" or the "Company") (OTC Pink ... ended January 31, 2009, a 13% increase over,revenues of ... growth in revenue is,attributable, in part, to more than ... service revenues. Versus, quarterly revenues can vary,significantly depending ...
... listed No. 1 in Health Care: Pharmacy and Other Services ... management worldwideFRANKLIN LAKES, N.J., March 6 Medco Health Solutions, ... position within the Health Care: Pharmacy and Other Services sector ... In addition, of all companies surveyed globally, Medco was ranked ...
... minorities than whites meet criteria for cutting-edge treatment , , ... Hispanic Medicare recipients suffer severe heart failure, they are ... with the most cutting-edge treatment available, a new analysis ... modest differences between racial and ethnic groups in the ...
... Today World Lung Foundation and the American Cancer Society ... online version of the document at TobaccoAtlas.org. This comprehensive ... how tobacco is devastating both global health and economies. ... Economy , According to The Tobacco Atlas, tobacco,s ...
... release is available in German . , ... in the treatment of certain brain tumours. This has been ... German and Swiss colleagues in a current study. They treated ... The patients survived on average 23 months; with the standard ...
Cached Medicine News:Health News:A Massage A Day at The Crossings 2Health News:Versus Technology Announces First Quarter Results 2Health News:Versus Technology Announces First Quarter Results 3Health News:Versus Technology Announces First Quarter Results 4Health News:Versus Technology Announces First Quarter Results 5Health News:Versus Technology Announces First Quarter Results 6Health News:Medco Tops Fortune's Lists of 'World's Most Admired' Companies 2Health News:Medco Tops Fortune's Lists of 'World's Most Admired' Companies 3Health News:Blacks, Hispanics Less Apt to Get Best Heart Failure Care 2Health News:Blacks, Hispanics Less Apt to Get Best Heart Failure Care 3Health News:New edition of the Tobacco Atlas catalogues catastrophic toll of tobacco worldwide 2Health News:New edition of the Tobacco Atlas catalogues catastrophic toll of tobacco worldwide 3Health News:Brain tumors: New therapy surprisingly successful 2
The Restoration GAP system addresses complex acetabular reconstruction with morselized graft through immobilization and proper compressive loading, the two mechanical factors influencing the integrat...
The MPF cup is specifically designed to achieve high primary stability, a critical factor for long term success....
Performa uncemented stem....
Porous foundation 480 series....
Medicine Products: